Rate My Professor Ben Brockway

Brockway's research focuses on exhaled breath analysis in disease and health, with particular emphasis on cystic fibrosis, asthma, and COPD, as well as biomarkers and airway diseases. As principal investigator for numerous studies and a member of the Otago Respiratory Research Unit, his work includes investigations into gene expression in antibiotic-resistant bacteria in cystic fibrosis, healthcare delivery for severe COPD, inhaled antibiotics for tuberculosis, and medication safety in COPD. Notable publications comprise "Duty of care? Tobacco laws and doctors in parliament" (Tobacco Control, 2024), "Cell-free DNA methylation in the clinical management of lung cancer" (Trends in Molecular Medicine, 2024), "Pseudomonas aeruginosa is oxygen-deprived during infection in cystic fibrosis lungs, reducing the effectiveness of antibiotics" (FEMS Microbiology Letters, 2023), and "Phase I trial of the single-chain urokinase intrapleural LTI-01 in complicated parapneumonic effusions or empyema" (JCI Insight, 2019). He has earned Dean's Commendations for Teaching in 2009, 2012, and 2015, along with the Dean's Senior Staff Award for Quality in Teaching in 2011. Previously Treasurer and Executive member of the Thoracic Society of Australia and New Zealand (TSANZ, NZ), he has contributed to the National Lung Cancer Working Group and Southern Island Lung Cancer Working Group, reviewed for the Health Research Council Clinical Trials Panel in 2014, and serves on the HRS and DSM Executive Boards. He is a member of PHSANZ, TSANZ, ATS, ERS, and ECFS.